Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
XE heads into the final stretch before its November 13 earnings with a week of genuine price recovery sitting on top of a deeply contested investment case.
The stock gained 8% over the past week to close at $15.45, a bounce that partially offsets a 13% decline over the prior month. The week's move is notable, but it leaves XE still well below the price levels at which most analysts initiated coverage earlier this year. That gap between the street's targets and the current price is the central tension in this note.
Options positioning is calm rather than charged, suggesting the weekly bounce has not triggered a rush of speculative interest. The put/call ratio is running at 0.74, slightly above its 20-day average of 0.65 but only 0.7 standard deviations above the mean. That is well within normal range and a long way from the 52-week high of 1.67. Options markets are neither crowded with bulls nor braced for a selloff, which is an unusual posture for a pre-commercial nuclear developer with binary milestones ahead.
The analyst picture is one of wide disagreement about valuation, and the most recent action cuts firmly to the downside. Piper Sandler initiated coverage on September 9 with an Underweight rating and a $9 target, roughly 42% below the current price. That contrasts sharply with Guggenheim's standing Buy at $57 and JP Morgan's Overweight at $38 (initiated in May). The consensus is technically a sell, though the spread between the $9 floor and the $57 ceiling signals that this is less a coherent view and more a collection of analysts who are simply not looking at the same company. The mean target across all coverage is $34.38, which is 2.2x the current price. At $15.45, the stock trades at 3.5x book value with deeply negative earnings and EV/EBITDA multiples that reflect the pre-revenue reality. The price-to-book multiple has compressed around 0.5 points over the past 30 days, consistent with the monthly price decline.
The ownership register is one of the most striking features of the XE story and deserves attention. Founder Kamal Ghaffarian controls roughly 25% of the class, a stake disclosed via Schedule 13G in August. Amazon holds 22.9% and Ares Partners disclosed 12.3%, both also on 13G filings from August. Together those three positions account for around 60% of the company. No 13D activist is on the register, meaning none of the large holders has signalled an intent to push for change. As always with 13D/G disclosures, these are as-last-disclosed stakes around the 5% threshold, and positions can change without a further filing if a holder drops below that level. Still, the combination of a hyperscaler anchor, a major private credit firm, and a founder block creates a shareholder base that is unusually concentrated for a Nasdaq-listed small-cap.
Retail attention has picked up sharply. The ORTEX Wikipedia-views signal, which tracks the average of English Wikipedia article views and ORTEX page views against the stock's own 90-day history, registered a z-score of 3.1 in late September. That is well above normal and reflects a real spike in public interest, though this dataset is flagged as an attention measure rather than a financial leading indicator, so the connection to the November print is informational, not causal.
The bear case is not subtle. DOE's cost-share commitment for the Dow-Seadrift demonstration plant has already risen to $2.1 billion from $1.2 billion, implying a total project cost close to $4.2 billion before commercial construction has properly begun. The overnight capital cost is still undisclosed. No NRC approval for the core reactor exists yet, and TRISO-X, the fuel subsidiary, has no signed customer IP agreement. The bull case points to the February 2026 Part 70 license for TX-1, 80% construction completion, HALEU supply contracted with Centrus and General Matter, and $54 million in revenue and grant income in the second quarter alone. Both cases are coherent, which is precisely what makes the analyst spread so wide.
The next fixed milestone is the November 13 earnings release, where the direction of DOE cost-share commentary and any update on the NRC approval timeline will likely matter more to the stock than the revenue line itself.
See the live data behind this article on ORTEX.
Open XE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
